Literature DB >> 12573360

Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL.

Bo Angelin1, Paolo Parini, Mats Eriksson.   

Abstract

Reverse cholesterol transport is a complex process, which transfers cholesterol from peripheral cells to the liver for subsequent elimination as bile acids and neutral steroids. Although apo A-I in high density lipoproteins (HDL) is believed to have a crucial role in this process, clinical conditions with very low HDL cholesterol levels appear to maintain normal cholesterol excretion. On the other hand, infusion of 'artificial HDL' in the form of recombinant proapo A-I (4 g) liposome complexes results in increased fecal steroid excretion, corresponding to a removal of approximately 0.5 g cholesterol daily for up to 9 days. This occurs without evidence of increased cholesterol synthesis, and could not be reproduced by infusion of liposomes only. These data indicate that stimulation of reverse cholesterol transport may be induced by infusion of 'artificial HDL' in humans, and that a more detailed knowledge of this process may be useful in the treatment of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12573360     DOI: 10.1016/s1567-5688(02)00047-8

Source DB:  PubMed          Journal:  Atheroscler Suppl        ISSN: 1567-5688            Impact factor:   3.235


  9 in total

1.  ATP-binding cassette sterol transporters are differentially expressed in normal and diseased human gallbladder.

Authors:  Jai Hoon Yoon; Ho Soon Choi; Dae Won Jun; Kyo-Sang Yoo; Jin Lee; Sun Young Yang; Rahul Kuver
Journal:  Dig Dis Sci       Date:  2012-11-22       Impact factor: 3.199

Review 2.  Apo a-I modulating therapies.

Authors:  Stephen J Nicholls
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

Review 3.  Biliary cholesterol secretion: more than a simple ABC.

Authors:  Arne Dikkers; Uwe-Jf Tietge
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

Review 4.  Modifying the anti-inflammatory effects of high-density lipoprotein.

Authors:  Benjamin J Ansell; Gregg C Fonarow; Mohamad Navab; Alan M Fogelman
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

Review 5.  Biologic therapies for dyslipidemia.

Authors:  Michael H Davidson
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

6.  Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial.

Authors:  Stephen J Nicholls; Rishi Puri; Christie M Ballantyne; J Wouter Jukema; John J P Kastelein; Wolfgang Koenig; R Scott Wright; David Kallend; Peter Wijngaard; Marilyn Borgman; Kathy Wolski; Steven E Nissen
Journal:  JAMA Cardiol       Date:  2018-09-01       Impact factor: 14.676

7.  Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond.

Authors:  Belinda A Di Bartolo; Daniel J Scherer; Stephen J Nicholls
Journal:  Arch Med Sci       Date:  2016-10-24       Impact factor: 3.318

8.  Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux.

Authors:  Sandhya Sankaranarayanan; John F Oram; Bela F Asztalos; Ashley M Vaughan; Sissel Lund-Katz; Maria Pia Adorni; Michael C Phillips; George H Rothblat
Journal:  J Lipid Res       Date:  2008-09-30       Impact factor: 5.922

Review 9.  Biology of Cholangiocytes: From Bench to Bedside.

Authors:  Kyo-Sang Yoo; Woo Taek Lim; Ho Soon Choi
Journal:  Gut Liver       Date:  2016-09-15       Impact factor: 4.519

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.